Published in Br J Clin Pharmacol on July 01, 2002
Role of serotonin in the pathophysiology of the irritable bowel syndrome. Br J Pharmacol (2004) 1.43
Neuroinflammation in inflammatory bowel disease. J Neuroinflammation (2010) 1.18
Neurogenic and myogenic properties of pan-colonic motor patterns and their spatiotemporal organization in rats. PLoS One (2013) 0.95
Long-term efficacy and safety of ramosetron in the treatment of diarrhea-predominant irritable bowel syndrome. Clin Exp Gastroenterol (2013) 0.86
Slow transit constipation: a review of a colonic functional disorder. Clin Colon Rectal Surg (2008) 0.84
The specialty of colon and rectal surgery: its impact on patient care and role in academic medicine. Yale J Biol Med (2003) 0.81
Treatment functional GI disease: the complex pharmacology of serotonergic drugs. Br J Clin Pharmacol (2002) 0.75
Functional Disorders: Slow-Transit Constipation. Clin Colon Rectal Surg (2017) 0.75
Methionine enhances the contractile activity of human colon circular smooth muscle in vitro. J Korean Med Sci (2012) 0.75
The 5HT4 receptor agonist prucalopride suppresses abdominal nociception. Dokl Biol Sci (2015) 0.75
Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial. Lancet (2000) 10.36
International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin). Pharmacol Rev (1994) 7.11
Role of impaired gastric accommodation to a meal in functional dyspepsia. Gastroenterology (1998) 5.34
Risk indicators of delayed gastric emptying of solids in patients with functional dyspepsia. Gastroenterology (1996) 3.22
Involvement of nitric oxide in the reflex relaxation of the stomach to accommodate food or fluid. Nature (1991) 2.82
The release of 5-hydroxytryptamine in relation to pressure exerted on the intestinal mucosa. J Physiol (1959) 2.17
Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment Pharmacol Ther (2001) 2.04
Endocrine cells in human intestine: an immunocytochemical study. Gastroenterology (1983) 1.90
Identification and stimulation by serotonin of intrinsic sensory neurons of the submucosal plexus of the guinea pig gut: activity-induced expression of Fos immunoreactivity. J Neurosci (1992) 1.86
5-Hydroxytryptamine4 receptor agonists initiate the peristaltic reflex in human, rat, and guinea pig intestine. Gastroenterology (1998) 1.78
Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist. Aliment Pharmacol Ther (1999) 1.66
Adrenergic modulation of human colonic motor and sensory function. Am J Physiol (1997) 1.59
The abdominal visceral innervation and the emetic reflex: pathways, pharmacology, and plasticity. Can J Physiol Pharmacol (1990) 1.55
Selective 5-hydroxytryptamine type 3 receptor antagonism with ondansetron as treatment for diarrhea-predominant irritable bowel syndrome: a pilot study. Mayo Clin Proc (1992) 1.53
Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome. Gastroenterology (2000) 1.45
Cisapride accelerates colonic transit in constipated patients with colonic inertia. Am J Gastroenterol (1989) 1.42
Involvement of 5-hydroxytryptamine, prostaglandin E2, and cyclic adenosine monophosphate in cholera toxin-induced fluid secretion in the small intestine of the rat in vivo. Gastroenterology (1989) 1.39
Antiemetic activity of ondansetron in acute gastroenteritis. Aliment Pharmacol Ther (1997) 1.36
Influence of sumatriptan on gastric fundus tone and on the perception of gastric distension in man. Gut (2000) 1.34
Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome. Aliment Pharmacol Ther (1998) 1.33
Selective stimulation of colonic transit by the benzofuran 5HT4 agonist, prucalopride, in healthy humans. Gut (1999) 1.31
Changes in serotonin metabolism in cancer patients: its relationship to nausea and vomiting induced by chemotherapeutic drugs. Br J Cancer (1992) 1.31
Pain is temporally related to eating but not to defaecation in the irritable bowel syndrome (IBS). Patients' description of diarrhea, constipation and symptom variation during a prospective 6-week study. Eur J Gastroenterol Hepatol (1998) 1.29
Participation of 5-HT3, 5-HT4, and nicotinic receptors in the peristaltic reflex of guinea pig distal colon. Am J Physiol (1996) 1.29
5-HT released by mucosal stimuli initiates peristalsis by activating 5-HT4/5-HT1p receptors on sensory CGRP neurons. Am J Physiol (1996) 1.27
Effects of a serotonin 5-HT(4) receptor antagonist SB-207266 on gastrointestinal motor and sensory function in humans. Gut (2000) 1.23
Meta-analysis of antisecretory and gastrokinetic compounds in functional dyspepsia. J Clin Gastroenterol (1998) 1.22
Gastric accommodation in non-ulcer dyspepsia and the roles of Helicobacter pylori infection and vagal function. Gut (1999) 1.22
Distinct 5-HT receptors mediate the peristaltic reflex induced by mucosal stimuli in human and guinea pig intestine. Gastroenterology (1996) 1.22
Alosetron relieves pain and improves bowel function compared with mebeverine in female nonconstipated irritable bowel syndrome patients. Aliment Pharmacol Ther (1999) 1.21
GR 38032F (ondansetron), a selective 5HT3 receptor antagonist, slows colonic transit in healthy man. Dig Dis Sci (1990) 1.20
The influence of cisapride on gastric tone and the perception of gastric distension. Aliment Pharmacol Ther (1998) 1.18
A 5HT3 antagonist corrects the postprandial colonic hypertonic response in carcinoid diarrhea. Gastroenterology (1994) 1.14
A double-blind, randomized, placebo-controlled dose-ranging study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther (2000) 1.13
Influence of antidepressants on whole gut and orocaecal transit times in health and irritable bowel syndrome. Aliment Pharmacol Ther (1994) 1.11
Effects of cisapride on cholinergic neurotransmission and propulsive motility in the guinea pig ileum. Gastroenterology (1989) 1.09
Evidence for the involvement of a 5-HT4 receptor in the secretory response of human small intestine to 5-HT. Br J Pharmacol (1993) 1.09
Colonic transit in man is slowed by ondansetron (GR38032F), a selective 5-hydroxytryptamine receptor (type 3) antagonist. Aliment Pharmacol Ther (1990) 1.05
Division of the irritable bowel syndrome into subgroups on the basis of daily recorded symptoms in two outpatients samples. Scand J Gastroenterol (1999) 1.04
Alosetron, a 5-HT3 receptor antagonist, delays colonic transit in patients with irritable bowel syndrome and healthy volunteers. Aliment Pharmacol Ther (2000) 1.02
Effect of cisapride on the gastrointestinal transit of a solid meal in normal human subjects. Gut (1987) 1.02
Reduction of rectal sensitivity and post-prandial motility by granisetron, a 5 HT3-receptor antagonist, in patients with irritable bowel syndrome. Aliment Pharmacol Ther (1993) 1.00
Differential 5-HT3 mediation of human gastrocolonic response and colonic peristaltic reflex. Am J Physiol (1998) 0.99
The inhibition of cholera toxin-induced 5-HT release by the 5-HT(3) receptor antagonist, granisetron, in the rat. Br J Pharmacol (2000) 0.97
In vivo effects of the 5-HT3 antagonist alosetron on basal and cholera toxin-induced secretion in the human jejunum: a segmental perfusion study. Aliment Pharmacol Ther (1997) 0.97
Efficacy of cisapride therapy in functional dyspepsia. Aliment Pharmacol Ther (1995) 0.94
Cisplatin increases the release of 5-hydroxytryptamine (5-HT) from the isolated vascularly perfused small intestine of the guinea-pig: involvement of 5-HT3 receptors. Naunyn Schmiedebergs Arch Pharmacol (1991) 0.94
Treatment of chronic constipation with cisapride and placebo. Gut (1987) 0.93
Effect of prucalopride, a new enterokinetic agent, on gastrointestinal transit and anorectal function in healthy volunteers. Aliment Pharmacol Ther (1999) 0.92
Effects of 5-hydroxytryptamine (5-HT) on the discharge of vagal mechanoreceptors and motility in the upper gastrointestinal tract of the ferret. J Auton Nerv Syst (1993) 0.92
Serotonin release into blood after food and pentagastrin. Studies in healthy subjects and in patients with metastatic carcinoid tumors. Gastroenterology (1986) 0.91
Intestinal motility changes in rats after enteric serotonergic neuron destruction. Am J Physiol (1991) 0.90
The role of nitric oxide (NO) in 5-HT-induced relaxations of the guinea-pig stomach. Naunyn Schmiedebergs Arch Pharmacol (1993) 0.88
Activation of 5-HT1P receptors on submucosal afferents subsequently triggers VIP neurons and chloride secretion in the guinea-pig colon. J Auton Nerv Syst (1997) 0.88
Modification of visceral sensitivity and pain in irritable bowel syndrome by 5-HT3 antagonism (ondansetron). Digestion (1997) 0.87
Comparative effects of levosulpiride and cisapride on gastric emptying and symptoms in patients with functional dyspepsia and gastroparesis. Aliment Pharmacol Ther (2000) 0.87
"Prokinetic" treatment of constipation-predominant irritable bowel syndrome: a placebo-controlled study of cisapride. J Clin Gastroenterol (1991) 0.87
Nitric oxide is a neurotransmitter in the chloride secretory response to serotonin in rat colon. Surgery (2000) 0.86
Serotonin receptor physiology: relation to emesis. Dig Dis Sci (1999) 0.86
The symptomatic effect of cisapride in patients with irritable bowel syndrome and constipation. Scand J Gastroenterol (1998) 0.84
Clinical pharmacodynamics of SDZ HTF 919, a new 5-HT4 receptor agonist, in a model of slow colonic transit. Clin Pharmacol Ther (1997) 0.84
The role of the 5-HT4 receptor in Cl- secretion in human jejunal mucosa. Eur J Pharmacol (1996) 0.84
The effect of cisapride on segmental colonic transit time in patients with spinal cord injury. Am J Gastroenterol (1995) 0.84
5-hydroxytryptamine-3 receptors are involved in the initiation of gastric phase-3 motor activity in humans. Gastroenterology (1993) 0.84
Ascending colon response to feeding: evidence for a 5-hydroxytryptamine-3 mechanism. Scand J Gastroenterol (1995) 0.83
Involvement of 5-hydroxytryptamine 3 receptors in regulation of interdigestive gastric contractions by motilin in the dog. Gastroenterology (1991) 0.83
Serotonin stimulates migrating myoelectric complex via 5-HT3-receptors dependent on cholinergic pathways in rat small intestine. Neurogastroenterol Motil (1999) 0.83
Cisapride in functional dyspepsia in general practice. A placebo-controlled, randomized, double-blind study. Aliment Pharmacol Ther (1997) 0.82
L-Type calcium channels in enterochromaffin cells from guinea pig and human duodenal crypts: an in situ study. Gastroenterology (1999) 0.82
Double-blind study of the effect of cisapride on constipation and abdominal discomfort as components of the irritable bowel syndrome. Aliment Pharmacol Ther (1997) 0.81
Fine structural classification and comparative distribution of endocrine cells in normal human large intestine. Gastroenterology (1978) 0.81
Gastric antisecretory effect of serotonin: quantitation of release and site of action. Am J Physiol (1996) 0.79
Concentration-dependent stimulation of intestinal phase III of migrating motor complex by circulating serotonin in humans. Clin Sci (Lond) (1998) 0.78
The effect of cisapride on dysmotility-like functional dyspepsia: reduction of the fasting and postprandial area, but not of the postprandial antral expansion. Eur J Gastroenterol Hepatol (1998) 0.78
Post-synaptic 5-HT4 receptor modulation of tachykinergic excitation of rat oesophageal tunica muscularis mucosae. Eur J Pharmacol (1997) 0.77
Functional Dyspepsia: Impaired Fundic Accommodation. Curr Treat Options Gastroenterol (2000) 0.77
Bacteriotherapy for Clostridium difficile diarrhoea. Lancet (1990) 0.76
BRL 24924, a 5-hydroxytryptamine type 3 antagonist, and gastric secretion of acid and pepsin in vivo. Digestion (1991) 0.76